Skip to main content
رجوع
LJUIF logo

SSY Group Limited

جودة البيانات: 100%
ذروة شراء
LJUIF
OTC Healthcare Drug Manufacturers - Specialty & Generic
KWD 0.40
KWD 0.00 (0.00%)
القيمة السوقية: 1.19B
نطاق اليوم
KWD 0.40 KWD 0.70
نطاق 52 أسبوعًا
KWD 0.40 KWD 0.70
حجم التداول
700
متوسط 50 يوم / 200 يوم
KWD 0.40 / KWD 0.48
الإغلاق السابق
KWD 0.40

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 1.1 0.3
P/B 0.2 2.9
ROE % 15.0 3.7
Net Margin % 18.4 3.8
Rev Growth 5Y % 7.9 10.0
D/E 0.5 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2027 KWD 0.288
KWD 0.261 – KWD 0.329
5.1 B 1
FY2026 KWD 0.219
KWD 0.198 – KWD 0.249
4.8 B 1

النقاط الرئيسية

Revenue grew 7.89% annually over 5 years — modest growth
Earnings declined -19.53% over the past year
ROE of 15.00% — decent returns on equity
Net margin of 18.38% shows strong profitability
Debt/Equity of 0.50 — conservative balance sheet
Negative free cash flow of -49.39M

النمو

Revenue Growth (5Y)
7.89%
Revenue (1Y)-10.67%
Earnings (1Y)-19.53%
FCF Growth (3Y)N/A

الجودة

Return on Equity
15.00%
ROIC9.28%
Net Margin18.38%
Op. Margin23.27%

الأمان

Debt / Equity
0.50
Current Ratio2.78
Interest Coverage10.59

التقييم

P/E Ratio
1.12
P/B Ratio0.16
EV/EBITDA2.66
Dividend Yield0.03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -10.67% Revenue Growth (3Y) -5.27%
Earnings Growth (1Y) -19.53% Earnings Growth (3Y) -2.79%
Revenue Growth (5Y) 7.89% Earnings Growth (5Y) 14.75%
Profitability
Revenue (TTM) 5.77B Net Income (TTM) 1.06B
ROE 15.00% ROA 8.42%
Gross Margin 50.37% Operating Margin 23.27%
Net Margin 18.38% Free Cash Flow (TTM) -49.39M
ROIC 9.28% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.50 Current Ratio 2.78
Interest Coverage 10.59 Dividend Yield 0.03%
Valuation
P/E Ratio 1.12 P/B Ratio 0.16
P/S Ratio 0.21 PEG Ratio -0.83
EV/EBITDA 2.66 Dividend Yield 0.03%
Market Cap 1.19B Enterprise Value 3.57B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 5.77B 6.46B 6.43B 5.36B 4.26B
Net Income 1.06B 1.32B 1.12B 785.53M 611.97M
EPS (Diluted) 0.36 0.44 0.38 0.26 0.20
Gross Profit 2.91B 3.62B 3.44B 3.04B 2.58B
Operating Income 1.34B 1.64B 1.42B 988.09M 758.88M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 12.60B 11.97B 10.97B 10.71B 9.25B
Total Liabilities 5.07B 4.70B 4.42B 4.22B 3.34B
Shareholders' Equity 7.22B 6.93B 6.21B 6.22B 5.65B
Total Debt 3.64B 3.37B 3.21B 3.11B 2.44B
Cash & Equivalents 1.26B 1.62B 1.71B 1.69B 1.45B
Current Assets 5.06B 5.12B 4.88B 4.88B 4.26B
Current Liabilities 1.82B 2.52B 2.68B 2.39B 2.12B

درجات الاستراتيجيات

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches

النشاط الأخير

دخل Contrarian Investing (David Dreman)
Mar 24, 2026
دخل Defensive Investing (Benjamin Graham)
Mar 24, 2026